Skip to main content
Premium Trial:

Request an Annual Quote

Axiom Will Adapt Screening Technology to Bioinformatics Database


SAN DIEGO--Axiom Biotech nolo gies has announced plans to use its proprietary High-Throughput Pharmacological Screening (HT-PS) system technology as a platform to develop a new bioinformatics resource, the PharmaProfile database. The database would correlate chemical structures with potential biological activity, potency, and selectivity, enabling drug research ers to rapidly evaluate drug candidate feasibility and accelerate the enhancement of lead potency and specificity by directing compound optimization strategies, according to the company.

The first HT-PS system is scheduled to be delivered and licensed to Cadus Pharmaceutical Corp., Tarrytown, N.Y., after Cadus invested $2 million in Axiom's preferred stock. The investment represents approximately a 26 percent stake in Axiom. If Cadus receives and accepts the system within a contractually specified time, it will buy another $2 million in preferred stock, raising its share of Axiom to 38 percent.

Cadus is engaged in the discovery of novel small-molecule therapeutics, with a particular emphasis on the development of proprietary technologies that exploit the similarities between yeast and human genomes. Axiom's primary focus is accelerating the drug development process through high-throughput pharmacological screening and more efficient lead compound optimization. The proprietary HT-PS system measures immediate physiological responses of human cells, automating the process of assessing the pharmacological properties of potential therapeutic compounds, according to Axiom.

In conjunction with Cadus's investment in Axiom, Jeremy Levin and Philip Sussman, respectively Cadus's CEO and vice-president of corporate development, were appointed to Axiom's board of directors, where they join Pandi Veerapandian and Ilya Okun, Axiom's president and chief scientific officer, and vice-president of pharmacology.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.